|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||32.55 - 33.05|
|52-week range||32.55 - 33.05|
|Beta (5Y monthly)||1.46|
|PE ratio (TTM)||29.10|
|Earnings date||21 Feb 2022 - 25 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Halozyme (HALO) third-quarter earnings and sales beat estimates. The company raises the lower end of its previously guided range for earnings and revenues for 2021. Stock up.